Table 1.
Characteristics of trial population exposed to treatment
| Characteristic | IDegAsp once daily (n = 230) | IGlar once daily (n = 233) |
|---|---|---|
| Sex: men/women, % | 58.7/41.3 | 54.5/45.5 |
| Age, years | 57.8 (9.5) | 58.4 (10.1) |
| Weight, kg | 84.7 (19.9) | 83.9 (19.2) |
| BMI, kg/m2 | 30.1 (5.1) | 30.1 (5.3) |
| Country of residence, n (%) | ||
| Croatia | 11 (4.8) | 11 (4.7) |
| France | 11 (4.8) | 10 (4.3) |
| India | 61 (26.5) | 47 (20.2) |
| Poland | 21 (9.1) | 11 (4.7) |
| South Africa | 10 (4.3) | 14 (6.0) |
| South Korea | 19 (8.3) | 23 (9.9) |
| Sweden | 18 (7.8) | 20 (8.6) |
| Turkey | 17 (7.4) | 16 (6.9) |
| USA | 62 (27.0) | 81 (34.8) |
| Duration of diabetes, years | 11.6 (6.8) | 11.4 (7.3) |
| HbA1c *, mmol/mol | 67.2 | 68.3 |
| HbA1c, % | 8.3 (0.8) | 8.4 (1.0) |
| FPG, mmol/l | 8.0 (2.5)‡ | 7.8 (2.8)† |
| FPG*, mg/dl | 144 (45) | 140 (50) |
| Prestudy treatment regimen, n (%) | ||
| Basal insulin + metformin | 94 (40.9) | 96 (41.2) |
| Basal insulin + metformin + other OADs† | 109 (47.4) | 108 (46.4) |
| Basal insulin + metformin + pioglitazone | 27 (11.7) | 29 (12.4) |
FPG, fasting plasma glucose; IDegAsp, insulin degludec/insulin aspart; IGlar, insulin glargine; OAD, oral antidiabetic drug.
All data are means (sd), unless otherwise specified.
*Calculated, not measured.
†40.2% of participants were on one OAD at screening; 45.1% of participants used two OADs (biguanide was used by all these participants and the second OAD was most commonly sulphonylurea or glinide). Thiazolidinedione was used by ~12.1% of participants overall. All OADs other than metformin, pioglitazone and dipeptidyl peptidase‐4 inhibitors were discontinued at the start of the trial period.
‡ n = 228;† n = 231.